The Relationship Between Sarcopenia and Cancer Chemotherapys

As an independent disease, characterized by progressive and generalized loss of skeletal muscle mass, quality and strength, Sarcopenia has become a research hotspot in recent years, and its position in cancer patients has been increasingly valued by clinicians. Clarifying the relationship between Sarcopenia and chemotherapeutics in the treatment of cancer patients will help to formulate interventions for Sarcopenia to improve the quality of life and prolong survival period of cancer patients. In order to understand the relationship between Sarcopenia and cancer chemotherapy, we review from the following aspects. How is Sarcopenia diagnosed in cancer patients? How to evaluate Sarcopenia in cancer patients? What is the incidence of Sarcopenia in cancer patients? What is the relationship between the changes in body composition and the dose of chemotherapy in cancer patients? Whether there is a relationship between Sarcopenia and chemotherapy-related toxicity in cancer patients? Its role in leading to chemotherapy toxicity and its effect on the prognosis and survival in cancer patients. Whether chemotherapeutic drugs have an effect on the development of Sarcopenia in cancer patients, or whether certain types of chemotherapy drugs will affect Sarcopenia? Finally, the review also aims to describe interventions for Sarcopenia and their impact on the outcome of treatment for cancer patients.